Tropomyosin-induced arthritis in rats

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Baharav, Ehud ^a   Mor, Felix ^a,b   Halpern, Marisa ^a,c   Quintana, Francisco ^b   Weinberger, Abraham ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti tumor necrosis factor ; Arthritis; Cytokines; Tropomyosin

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 14; NEUTRALIZING ANTIBODY; TROPOMYOSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ALPHA TROPOMYOSIN; CYTOKINE; INTERLEUKIN 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BEHCET DISEASE; BONE DISEASE; CELL INFILTRATION; CHONDROPATHY; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FIBROSIS; FOLLOW UP; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MALE; MONONUCLEAR CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RAT; TH1 CELL; BONE INJURY; CHRONIC ARTHRITIS; CYTOKINE RELEASE; LEG DISEASE; LEWIS RAT; SEX DIFFERENCE; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ARTHRITIS, EXPERIMENTAL; BEHCET SYNDROME; DISEASE MODELS, ANIMAL; MUSCLE PROTEINS; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; TOE JOINT; TROPOMYOSIN;

EID: 35449005408     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. MOR F, WEINBERGER A, COHEN IR: Identification of alpha-tropomyosin as a target self-antigen in Behçet's syndrome. Eur J Immunol 2002; 32: 35.
2. LEES-MILLER JP, HELFMAN DM: The molecular basis for tropomyosin isoform diversity. BioEssays 1991; 13: 429-37.
3. BIANCONE L, MONTELEONE G, MARASCO R, PALLONE F: Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol 1998; 113: 198-205.
4. TANIGUCHI M, GENG X, GLAZIER KD, DASGUPTA A, LIN J J, DAS KM: Cellular immune response against tropomyosin isoform 5 in ulcerative colitis. Clin Immunol 2001; 101: 289-95.
5. ASTURIAS JA, GOMEZ-BAYON N, ARILLA MC et al.: Molecular characterization of American cockroach tropomyosin (Periplaneta americana allergen 7), a cross-reactive allergen. J Immunol 1999; 162: 4342-8.
6. RUIZ-OPAZO N, NADAL-GINARD B: Alphatropomyosin gene organization. Alternative splicing of duplicated isotype-specific exons accounts for the production of smooth and striated muscle isoforms. J Biol Chem 1987; 262: 4755-65.
7. LEMONNIER M, BALVAY L, MOULY V, LIBRI D, FISZMAN MY: The chicken gene encoding the alpha isoform of tropomyosin of fasttwitch muscle fibers: organization, expression and identification of the major proteins synthesized. Gene 1991; 107: 229-40.
8. AKI T, KODAMA T, FUJIKAWA A et al.: Immunochemical characterization of recombinant and native tropomyosins as a new allergen from the house dust mite, Dermatophagoides farinae. J Allergy Clin Immunol 1995; 96: 74-83.
9. Rodent diet data, 2018S [Online]. http://www.taklad.com
10. CULIGAN TE, KRNISBEEK AM, MARGULIS DH, SHERACH EM, STROBER W, editors. Adjuvant arthritis in the rat. Current Protocols in Immunology. Suppl 19. New York: John Wiley & Sons, Inc 1996: 15.4.1.-15.4.7.
11. OZDEMIR M, BALEVI S, DENIZ F, MEVLITOGLU I: Pathergy reaction in different body areas in Behçet's disease. Clin Exp Dermatol 2007; 32: 85-7.
12. GOLDENBERG DL, CHISHOLM PL, RICE PA: Experimental models of bacterial arthritis: A microbiologic and histopathologic characterization of the arthritis after the intraarticular injections of Neisseria gonorrheae, Staphylococcus aureus, group A streptococci, and Escherichia coli. J Rheumatol 1983; 1: 5-11.
13. STANESCU R, LIDER O, VAN EDEN W, HOLOSHITZ J, COHEN IR: Histopathology of arthritis induced in rats by active immunization to mycobacterial antigens or by systemic transfer of T lymphocyte lines. A light and electron microscopic study of the articular surface using cationized ferritin. Arthritis Rheum 1987; 30: 779-92.
14. TUGAL-TUTKUN I, ONAL S, ALTAN-YAYCIOGLU R, ALTUNBAS H, URGANCIOGLU M: Uveitis in Behçet's disease: An analysis of 880 patients. Am J Ophthalmol. 2004; 138: 373-80.
15. PETTY RE, HUNT DW, MATHERS DM et al.: Experimental arthritis and uveitis in rats associated with Mycobacterium butyricum. J Rheumatol 1994; 21: 1491-6.
16. DE VOS AF, DICK AD, KLOOSTER J, BROERSMA L, MCMENAMIN PG, KIJLSTRA A: Analysis of the Cellular Infiltrate in the Iris during Experimental Autoimmune Encephalomyelitis, Invest Ophthalmol Vis Sci 2000; 41: 3001-10.
17. FUKUSHIMA A, YAMAGUCHI T, ISHIDA W, FUKATA K, OZAKI A, UENO H: The immunization protocol determines whether endogenous interferon-gamma suppresses the infiltration of eosinophils into the conjunctiva. Immunol Lett 2005; 100: 189-94.
18. BURLINGHAM WJ, JANKOWSKA-GAN E: Mouse Strain and Injection Site are Crucial for Detecting Linked Suppression in Transplant Recipients by Trans-Vivo DTH Assay. Am J Transplantation 2007; 7:466-470
19. http://www.ncbi.nlm.nih.gov/blast/b12seq/wblast2.cgi?0
20. MAHESH SP, LI Z, BUGGAGE R et al.: Alpha tropomyosin as a self-antigen in patients with Behçet's disease. Clin Exp Immunol 2005; 140: 368-75.
21. MILLER A, LIDER O, WEINER HL: Antigendriven bystander suppression after oral administration of antigens. J Ex Med 199; 174: 791-8.
22. MISUMI M, HAGIWARA E, TAKENO M et al.: Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine 2003; 24: 210-8.
23. MELIKOGLU M, FRESKO I, MAT C et al.: Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
24. KULMATYCKI KM, ABOUCHEHADE K, SATTARI S, JAMALI F: Drug-disease interactions: Reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 2001; 133; 286-94.
25. ONDA A, MURATA Y, RYDEVIK B, LARSSON K, KIKUCHI S, OLMARKER K: Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine. 2004; 29:1857-61.
26. FRASSANITO MA, DAMMACCO R, CAFFORIO P, DAMMACCO F: Th1 polarization of the immune response in Behçet's disease: A putative pathogenefic role of interleukin-12. Arthritis Rheum 1999; 42: 1967-74.
27. ERTENLI I, KIRAZ S, CALGUNERI M et al.: Synovial fluid cytokine levels in Behçet's disease. Clin Exp Rheumatol 2001; 19: S37-41.
28. BEN AHMED M, HOUMAN H, MILED M, DELLAGI K, LOUZIR H: Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum 2004; 50: 2291-5.
29. TRIOLO G, ACCARDO-PALUMBO A, DIELI F et al.: Humoral and cell mediated immune response to cow's milk proteins in Behçet's disease. Ann Rheum Dis. 2002; 61: 459-62.
30. ARIDOGAN BC, YILDIRIM M, BAYSAL V, INALOZ HS, BAZ K, KAYA S: Semm Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J Dermatol 2003; 30: 602-7.
31. + T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behçet's disease. Rheumatology (Oxford) 2004; 43: 843 -51.
32. YAZICI H: The place of Behçet's syndrome among the autoimmune diseases, Int Rev Immunol 1997; 14: 1-10.
33. BAHARAV E, MOR F, HALPERN M, WEINBERGER A: Probiotic bacteria Lactobacillus GG ameliorates experimental arthritis. J Nutrition 2004; 134: 1964-69.